Cargando…

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, Andrew R, Aleskandarany, Mohammed A, Agarwal, Devika, Elsheikh, Somaia, Nolan, Christopher C, Diez-Rodriguez, Maria, Macmillan, R Douglas, Ball, Graham R, Caldas, Carlos, Madhusudan, Srinivasan, Ellis, Ian O, Rakha, Emad A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984797/ https://www.ncbi.nlm.nih.gov/pubmed/26954716 http://dx.doi.org/10.1038/bjc.2016.46

Ejemplares similares

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
por: Craze, Madeleine L, et al.
Publicado: (2018)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2017)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers
por: Green, A R, et al.
Publicado: (2013)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer
por: Alshareeda, A T, et al.
Publicado: (2015)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
por: Elsheikh, S E, et al.
Publicado: (2008)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
por: Al-kaabi, M M, et al.
Publicado: (2015)

SCN1A Genetic Test for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy and its Clinical Subtypes) for use in the Diagnosis, Prognosis, Treatment and Management of Dravet Syndrome
por: Stenhouse, Susan A.R., et al.
Publicado: (2013)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
por: Kristiansen, G, et al.
Publicado: (2010)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

Clinicopathologic and molecular predictors of axillary lymph node metastasis in early-stage breast cancer: a mathematical predictive model
por: Aleskandarany, MA, et al.
Publicado: (2010)

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
por: Sung, Hyuna, et al.
Publicado: (2016)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
por: Sternemalm, J, et al.
Publicado: (2014)

Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network
por: Boult, J K R, et al.
Publicado: (2008)

Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer
por: Shamanna, Raghavendra A., et al.
Publicado: (2016)

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
por: Dawson, S-J, et al.
Publicado: (2010)

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair
por: Johnston, Simon J., et al.
Publicado: (2018)

ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC
por: Griffin, Nicolas I., et al.
Publicado: (2016)

Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts()
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer
por: Horii, R, et al.
Publicado: (2007)

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
por: Einama, T, et al.
Publicado: (2012)

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
por: Ursin, G, et al.
Publicado: (2005)

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease
por: Clark, S E, et al.
Publicado: (2011)

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
por: Seo, A N, et al.
Publicado: (2014)

WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma
por: Rogers, H A, et al.
Publicado: (2012)

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
por: Caiazza, F, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_odg0kqb096ha5cm6hb4t29l2cp